Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856289 | 0.84 | LMNA (0.51) | ALOX15LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2851489 | 0.79 | MRGPRX1 (0.44) | ALOX15LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2858937 | 0.78 | LMNA (0.48) | ALOX15LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2855370 | 0.76 | LMNA (0.46) | ALOX15LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2862606 | 0.75 | KDM4E (0.44) | ALOX15LMNAPOLBALDH1A1KMT2A | |
| SCHEMBL2855770 | 0.74 | LMNA (0.50) | ALOX15LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2857863 | 0.74 | LMNA (0.45) | ALOX15LMNACTSKGLA | |
| SCHEMBL2851496 | 0.72 | LMNA (0.48) | ALOX15LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2856326 | 0.72 | DPP4 (0.42) | — | |
| Acetic Acid SCHEMBL11738287 | 0.71 | SLC18A3 (0.44) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687630-B2 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | NQO1, SQLE, NQO2 | ALOX15 2249/4885LMNA 3341/4885POLB 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.